BC Extra | Sep 5, 2019
Company News

Sept. 5 Company Quick Takes: Zafgen exploring alternatives; plus BridgeBio, Global Blood, Akouos, Mallinckrodt, uBiome

Zafgen evaluating strategic options  Metabolic company Zafgen Inc. (NASDAQ:ZFGN) has retained advisory firm MTS Health Partners to explore strategic alternatives after receiving new preclinical data that the company believes will be insufficient for FDA to...
BC Extra | Aug 26, 2019
Company News

Management tracks: Grail, Boehringer, Torque, Bellus and Emerald

Liquid biopsy company Grail Inc. (Menlo Park, Calif.) hired Rodger Currie as VP and head of government affairs and alliance development. Currie was EVP for advocacy at PhRMA and previously served as VP of global...
BC Extra | Jul 24, 2019
Company News

July 24 Company Quick Takes: Samsung's Humira biosimilar gets FDA approval; plus Intra-Cellular, Sage and more

FDA approves Samsung's Humira biosimilar  Samsung Bioepis Co. Ltd. (Incheon, South Korea) said FDA approved Hadlima adalimumab-bwwd, a biosimilar of autoimmune drug Humira from AbbVie Inc. (NYSE:ABBV). Samsung's partner Merck & Co. Inc. (NYSE:MRK) will...
BC Extra | Jul 19, 2019
Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

Cancer immunotherapy company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Friedrich Graf Finckenstein as CMO. He was global head of oncology translational medicine of the Pharma Research and Early Development (pRED) unit of Roche (SIX:ROG; OTCQX:RHHBY). ViiV...
BC Extra | Mar 11, 2019
Clinical News

Setback for another Zafgen MetAP2 inhibitor

Zafgen lost $1.10 (24%) to $3.50 in after-hours trading Monday after the company said it suspended plans to submit an IND for Prader-Willi syndrome candidate ZGN-1258 based on findings of muscle degeneration and other anomalies...
BC Extra | Mar 4, 2019
Company News

Management tracks: Astellas, Sanofi China, Zafgen

Astellas promoted James Kellerman to SVP and head of IP legal and Peter Sandor to SVP and primary focus lead for immuno-oncology. Kellerman was VP of IP, Americas region and Sandor was VP, head of...
BC Week In Review | Jan 18, 2019
Clinical News

No safety signals with Zafgen's ZGN-1061 in second cohort of diabetes trial

Zafgen Inc. (NASDAQ:ZFGN) said the 1.8 mg subcutaneous dose of ZGN-1061 met primary and secondary endpoints in a second dose cohort from a Phase II trial to treat Type II diabetes. The adverse event profile...
BC Week In Review | Nov 30, 2018
Clinical News

U.S. setback for Zafgen's diabetes therapy

Zafgen Inc. (NASDAQ:ZFGN) shares fell $3.69 (41%) to $5.41 Nov. 26 after it disclosed that FDA placed a clinical hold on an IND for ZGN-1061 to treat Type II diabetes. Zafgen said the agency cited...
BC Extra | Nov 26, 2018
Clinical News

U.S. setback for Zafgen's diabetes therapy

Zafgen Inc. (NASDAQ:ZFGN) shares fell $3.69 (41%) to $5.41 Monday after it disclosed that FDA placed a clinical hold on an IND for ZGN-1061 to treat Type II diabetes. Zafgen said the agency cited a...
BC Extra | Aug 3, 2018
Company News

Management tracks: Cellectis, Navitor

Zafgen Inc. (NASDAQ:ZFGN) CEO Thomas Hughes has stepped down from the metabolic disease company to become CEO at Navitor Pharmaceuticals Inc. (Cambridge, Mass.). Zafgen is seeking a successor. In June, Navitor begin Phase I testing...
Items per page:
1 - 10 of 114
BC Extra | Sep 5, 2019
Company News

Sept. 5 Company Quick Takes: Zafgen exploring alternatives; plus BridgeBio, Global Blood, Akouos, Mallinckrodt, uBiome

Zafgen evaluating strategic options  Metabolic company Zafgen Inc. (NASDAQ:ZFGN) has retained advisory firm MTS Health Partners to explore strategic alternatives after receiving new preclinical data that the company believes will be insufficient for FDA to...
BC Extra | Aug 26, 2019
Company News

Management tracks: Grail, Boehringer, Torque, Bellus and Emerald

Liquid biopsy company Grail Inc. (Menlo Park, Calif.) hired Rodger Currie as VP and head of government affairs and alliance development. Currie was EVP for advocacy at PhRMA and previously served as VP of global...
BC Extra | Jul 24, 2019
Company News

July 24 Company Quick Takes: Samsung's Humira biosimilar gets FDA approval; plus Intra-Cellular, Sage and more

FDA approves Samsung's Humira biosimilar  Samsung Bioepis Co. Ltd. (Incheon, South Korea) said FDA approved Hadlima adalimumab-bwwd, a biosimilar of autoimmune drug Humira from AbbVie Inc. (NYSE:ABBV). Samsung's partner Merck & Co. Inc. (NYSE:MRK) will...
BC Extra | Jul 19, 2019
Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

Cancer immunotherapy company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Friedrich Graf Finckenstein as CMO. He was global head of oncology translational medicine of the Pharma Research and Early Development (pRED) unit of Roche (SIX:ROG; OTCQX:RHHBY). ViiV...
BC Extra | Mar 11, 2019
Clinical News

Setback for another Zafgen MetAP2 inhibitor

Zafgen lost $1.10 (24%) to $3.50 in after-hours trading Monday after the company said it suspended plans to submit an IND for Prader-Willi syndrome candidate ZGN-1258 based on findings of muscle degeneration and other anomalies...
BC Extra | Mar 4, 2019
Company News

Management tracks: Astellas, Sanofi China, Zafgen

Astellas promoted James Kellerman to SVP and head of IP legal and Peter Sandor to SVP and primary focus lead for immuno-oncology. Kellerman was VP of IP, Americas region and Sandor was VP, head of...
BC Week In Review | Jan 18, 2019
Clinical News

No safety signals with Zafgen's ZGN-1061 in second cohort of diabetes trial

Zafgen Inc. (NASDAQ:ZFGN) said the 1.8 mg subcutaneous dose of ZGN-1061 met primary and secondary endpoints in a second dose cohort from a Phase II trial to treat Type II diabetes. The adverse event profile...
BC Week In Review | Nov 30, 2018
Clinical News

U.S. setback for Zafgen's diabetes therapy

Zafgen Inc. (NASDAQ:ZFGN) shares fell $3.69 (41%) to $5.41 Nov. 26 after it disclosed that FDA placed a clinical hold on an IND for ZGN-1061 to treat Type II diabetes. Zafgen said the agency cited...
BC Extra | Nov 26, 2018
Clinical News

U.S. setback for Zafgen's diabetes therapy

Zafgen Inc. (NASDAQ:ZFGN) shares fell $3.69 (41%) to $5.41 Monday after it disclosed that FDA placed a clinical hold on an IND for ZGN-1061 to treat Type II diabetes. Zafgen said the agency cited a...
BC Extra | Aug 3, 2018
Company News

Management tracks: Cellectis, Navitor

Zafgen Inc. (NASDAQ:ZFGN) CEO Thomas Hughes has stepped down from the metabolic disease company to become CEO at Navitor Pharmaceuticals Inc. (Cambridge, Mass.). Zafgen is seeking a successor. In June, Navitor begin Phase I testing...
Items per page:
1 - 10 of 114